title: Update on psoriasis immunopathogenesis and targeted immunotherapy.
abstract: Over recent years, significant progress has been made in characterisation of the underlying pathogenic mechanisms in psoriasis, a common cutaneous disease that is associated with major systemic co-morbidity and reduced life expectancy. Basic science discoveries have informed the design of novel therapeutic approaches, many of which are now under evaluation in late-stage clinical trials. Here we describe the complex interplay between immune cell types and cytokine networks that acts within self-perpetuating feedback loops to drive cutaneous inflammation in psoriasis. Genetic studies have been pivotal in the construction of the disease model and more recently have uncovered a distinct aetiology for rare, pustular variants of psoriasis. The translation of mechanistic insights into potential advancements in clinical care will also be described, including several treatments that target the interleukin-23 (IL-23)/T17 immune axis.
authors.affiliation: St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London, London, UK.
authors.forename: Satveer K
authors.initials: SK
authors.lastname: Mahil
authors.affiliation: Department of Medical and Molecular Genetics, Division of Genetics and Molecular Medicine, King's College London, London, UK.
authors.forename: Francesca
authors.initials: F
authors.lastname: Capon
authors.affiliation: St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London, London, UK. jonathan.barker@kcl.ac.uk.
authors.forename: Jonathan N
authors.initials: JN
authors.lastname: Barker
mesh_terms: D000818:Animals; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007107:Immune System / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D011565:Psoriasis / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*
chemical_list: D016207:Cytokines